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Type 2 diabetes (T2D) results from insulin resistance and
inadequate insulin secretion. Insulin resistance initially causes
compensatory islet hyperplasia that progresses to islet disorga-
nization and altered vascularization, inﬂammation, and, ﬁnally,
decreased functional b-cell mass and hyperglycemia. The precise
mechanism(s) underlying b-cell failure remain to be elucidated.
In this study, we show that in insulin-resistant high-fat diet-fed
mice, the enhanced islet vascularization and inﬂammation was
parallel to an increased expression of vascular endothelial
growth factor A (VEGF). To elucidate the role of VEGF in these
processes, we have genetically engineered b-cells to overexpress
VEGF (in transgenic mice or after adeno-associated viral vector-
mediated gene transfer). We found that sustained increases in
b-cell VEGF levels led to disorganized, hypervascularized, and
ﬁbrotic islets, progressive macrophage inﬁltration, and proinﬂam-
matory cytokine production, including tumor necrosis factor-a
and interleukin-1b. This resulted in impaired insulin secretion,
decreased b-cell mass, and hyperglycemia with age. These results
indicate that sustained VEGF upregulation may participate in the
initiation of a process leading to b-cell failure and further suggest
that compensatory islet hyperplasia and hypervascularization
may contribute to progressive inﬂammation and b-cell mass loss
during T2D. Diabetes 61:2851–2861, 2012
Type 2 diabetes (T2D) results from inadequateinsulin secretion, which is unable to compensatefor insulin resistance, due to the combination ofdecreased b-cell mass and function (1–3). Al-
though defects in both insulin secretion and action contribute
to the pathogenesis of T2D, it is now recognized that insulin
deﬁciency is the critical constituent, without which T2D does
not develop. As b-cell secretory capacity deteriorates, glucose
tolerance worsens, eventually culminating in overt hypergly-
cemia (3). Post mortem studies revealed that type 2 diabetic
patients have reduced b-cell mass and increased b-cell apo-
ptosis rates (4,5). Loss of b-cell mass and function results
from persistent hyperglycemia and hyperlipidemia, together
with islet inﬂammation and increased proinﬂammatory cyto-
kine production (6–9). However, the mechanisms under-
pinning increased b-cell death remain to be elucidated.
In the early stages of T2D, expansion of b-cell mass is
a key adaptive response to compensate for insulin re-
sistance (2). During this period, islet vasculature also
needs to expand to perfuse the new b-cells (10). The for-
mation of vessels in adult organisms (angiogenesis) occurs
through a multistep process requiring vascular endothelial
growth factor A (VEGF) and other soluble factors (11,12).
VEGF recruits circulating monocytes and macrophages,
which are required for active angiogenesis (13). In adults,
VEGF is highly expressed and secreted by insulin-producing
b-cells and is responsible for the rich islet vascularization
(14–16). VEGF deﬁciency in b-cells does not modify b-cell
mass, but leads to insufﬁcient islet vascularization, which
results in defective insulin secretion and glucose in-
tolerance (14,17). However, this deﬁciency does not impair
b-cell mass growth during a high-fat diet (HFD); contrarily,
it results in a slightly increased b-cell mass (18). Further-
more, islet vascular abnormalities have been described in
several animal models of T2D. Prior to developing hyper-
glycemia, islets from Zucker diabetic fatty rats show vessel
remodeling with expansion of endothelial cells and higher
VEGF secretion (19). Similarly, pancreatic islets from
spontaneously diabetic Torii rats are ﬁbrotic with vascular
alterations preceding hyperglycemia (20). Goto-Kakizaki
(GK) rats also show endothelial hypertrophy with in-
creased expression of vessel extracellular matrix compo-
nents (21), and Otsuka Long-Evans Tokushima fatty rats
display ﬁbrosis and vascular abnormalities in islets (22).
Finally, db/db mice develop irregular vessels with in-
creased mean capillary size, edema, and ﬁbrosis (23). In
mouse islets, endothelial cells synthesize extracellular
matrix (ECM) components surrounding b-cells (24–26).
ECM accumulation surrounding islet vessels in T2D mod-
els can progress to ﬁbrosis that disrupts islet structure
(21). Taken together, these studies suggest that alterations
in islet vasculature may precede and/or be involved in
b-cell dysfunction and death. Nevertheless, the role of
chronic islet hypervascularization in b-cell function and
loss in T2D is still not fully understood. In this study, by
genetically engineering b-cells to overexpress VEGF, we
demonstrate that sustained increases in VEGF levels leads
to islet hypervascularization, ﬁbrosis, and inﬂammation,
resulting in b-cell death and hyperglycemia.
RESEARCH DESIGN AND METHODS
Animals. C57Bl6/SJL transgenic mice expressing murine VEGF164 (provided
by P.A. D’Amore, Boston, MA) under the control of the rat insulin promoter-I
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(RIP-I) were obtained by embryo pronuclear microinjection. Both VEGFlow
and VEGFhigh transgenic mice were born at the expected frequencies and
fertile, and they did not develop tumors when old (.14 months). Two-
month-old C57Bl6/SJL mice were used for adeno-associated viral (AAV) vector
treatment. Diabetes was assessed by measuring tail vein blood glucose levels
using a Glucometer Elite analyzer (Bayer). Mice were fed ad libitum with
a standard chow diet (Basal Puriﬁed Diet with 12% energy from fat) or an HFD
(Basal Puriﬁed Diet with 60% energy from fat, TD.88137; Harlan Teklad). In all
experiments, male mice were age-matched. Animal care and experimental
procedures were approved by the Ethics Committee in Animal and Human
Experimentation of the Universitat Autònoma de Barcelona.
VEGF and insulin determinations. VEGF levels in serum and islet homog-
enatesweremeasured byELISA (Calbiochem, Nothingam, U.K.). Insulin levels in
serum were determined by radioimmunoassay (Linco, St. Charles, MO).
Immunohistochemical analysis. Pancreata were ﬁxed for 24 h in formalin,
embedded in parafﬁn, and sectioned. For immunohistochemical detection of
insulin, glucagon, VEGF-A, CD31, Mac-2, and glucose transporter (GLUT)-2,
pancreatic sections were incubated overnight at 4°C with a guinea pig anti-
insulin antibody (Sigma Chemical, St. Louis, MO), a rabbit antiglucagon anti-
body (ICN Biomedicals Inc.), a mouse anti–VEGF-A antibody (Santa Cruz
Biochemicals), a rat anti-mouse CD31 antibody (BD Biosciences), a rabbit
anti–Mac-2 antibody (Cedarlane Laboratories), or a rabbit anti–GLUT-2 anti-
body (Chemicon International, Temecula, CA). Secondary antibodies were:
tetramethyl rhodamine isothiocyanate-conjugated goat anti-guinea pig (Mo-
lecular Probes, Leiden, the Netherlands); biotinylated goat anti-rabbit (Mo-
lecular Probes); biotinylated donkey anti-goat (Santa Cruz Biotechnology);
biotinylated rabbit anti-rat (DakoCytomation, Glostrup, Denmark); bio-
tinylated goat anti-rabbit (Molecular Probes); biotinylated horse anti-mouse
(Vector Laboratories, Burlingame, CA); streptavidin-conjugated Alexa 488
(Molecular Probes); or streptavidin-conjugated Alexa 568 (Molecular Probes).
For anti-mouse antibody detection, M.O.M kit (Vector Laboratories) was used.
Nuclei were counterstained with Hoechst (Sigma-Aldrich). Bright ﬁeld sec-
tions were counterstained with hematoxylin.
Fluorescein-dextran injection. To visualize vessels within the islets, a
dextran–ﬂuorescein isothiocyanate (FITC) solution (Sigma-Aldrich; 50 mg/mL
PBS) was administered by tail vein injection. After 10 min, animals were
sacriﬁced, and pancreata were ﬁxed for 12–24 h in formalin, embedded in
parafﬁn, and sectioned.
Morphometrical analysis. For morphometrical analysis of b-cell mass, im-
munohistochemical detection of insulin was performed in three (2 to 3 mm)
sections, separated by 200 mm in each animal. The percentage of b-cell area in
the pancreas was calculated by dividing the area of all insulin-positive cells in
one section by the total area of this section and multiplying the result by 100.
The b-cell mass was calculated by multiplying the pancreas weight by the
percent of b-cell area. For measurement of b-cell proliferation, replicating
b-cells were identiﬁed by double Ki67/insulin immunostaining. Apoptotic
b-cells were determined by double transferase-mediated dUTP nick-end la-
beling (TUNEL)/insulin immunostaining. At least 5,000 b-cells per pancreas
were counted. Four animals per group were used in each analysis. For mor-
phometrical analysis of islet vascularization, FITC-positive area and insulin-
positive area were determined in pancreatic sections from FITC-conjugated
dextran-injected animals. Macrophage inﬁltration was measured as the per-
centage of Mac-2–positive area per islet area. Islet vascularization and mac-
rophage inﬁltration were quantiﬁed by measuring islets from three different
sections per mouse, with four animals per group. A microscope (Eclipse E800;
Nikon, Tokyo, Japan) connected to an image analyzer was used. For laser-
scanning confocal analysis, a TCS SP2 microscope (Leica Microsystems,
Heidelberg, Germany) was used.
Isolation of islets. Pancreatic islets were isolated by intraductal injection
of collagenase solution (1 mg/mL collagenase P; Roche Molecular Bio-
chemicals, Mannheim, Germany) and digestion in Hanks’ balanced salt so-
lution (HBSS) containing 1% BSA and 5 mmol/L glucose for 10 min at 37°C.
Cold HBSS (with 1% BSA and 5 mmol/L glucose) was added to stop the
digestion. The tissue suspension was washed twice with cold HBSS. Islets
were handpicked.
Gene expression analysis. For quantitative RT-PCR analysis, total RNA was
extracted from isolated islets using Tripure Isolation Reagent (RocheMolecular
Biochemicals) and RNeasy Mini Kits (Qiagen, Hilden, Germany). Total RNA
(1 mg) was reverse-transcribed for 1 h at 37°C using the Omniscript Reverse
transcriptase kit (D-40724; Qiagen). Quantitative PCR (qPCR) was performed
in a SmartCycler II (Cepheid, Sunnyvale, CA) using the Quantitect SYBR green
kit (Qiagen).
For gene expression analysis, the following primers were used: interleukin-1b
(IL-1b) forward, 59-CAACCAACAAGTGATATTCTCCATG-39 and reverse, 59-
CATCCACACTCTCCAGCTGCA-39; tumor necrosis factor-a (TNF-a) forward,
59-CATCTTCTCAAAATTCGAGTGACAA-39 and reverse 59-TGGGAGTAGACA-
AGGTACAACCC-39; CCL-2 forward, 59-CCCAATGAGTAGGCTGGAGA-39 and
reverse, 59-TCTGGACCCATTCCTTCTTG-39; IL-6 forward, 59-AGTTGCCTTCTT-
GGGACTGA-39 and reverse, 59-TCCACGATTTCCCAGAGAAC-39; RBS forward,
59-ATTCGCTGCACGAACTGCG-39 and reverse, 59-CAGCAGGTCTGAATCGT-
GGT-39; and GLUT-2 forward, 59-CTGGAGCCCTCTTGATGGGA-39 and reverse,
59-CCAGTCCTGAAATTAGCCCAC-39.
Western blot analysis. Isolated islets were homogenized in protein lysis
buffer after being washed with PBS. Proteins (50–100 mg) were separated by
10% SDS-PAGE, transferred to polyvinylidene diﬂuoride membranes, and
probed with primary antibodies against VEGF (Abcam), E-cadherin (Santa
Cruz Biotechnology), and b-actin (Abcam) overnight at 4°C. Detection was
performed using horseradish peroxidase-labeled anti-goat immunoglobulin G
or horseradish peroxidase-labeled anti-rabbit immunoglobulin G (DakoCyto-
mation) and ECL Plus Western Blotting Detection Reagent (Amersham Bio-
sciences). Data were obtained from three pools of islets and four mice per
pool.
Recombinant AAV vectors. Vectors were generated by triple transfection of
human embryonic kidney 293 cells. Cells were cotransfected with a plasmid
carrying the expression cassette, a helper plasmid carrying the AAV rep2 and
cap9 genes, and a plasmid carrying the adenovirus helper functions (provided
by K.A. High, Children’s Hospital of Philadelphia). The transgene used in these
experiments was murine VEGF164 under the control of RIP-I promoter fol-
lowed by woodchuck hepatitis virus posttranscriptional regulatory element
sequence to increase expression. AAV null vectors were produced using
pAAV-MCS plasmid (Stratagene, La Jolla, CA). Vectors were puriﬁed with an
optimized method using cesium chloride gradients (27), dialyzed, ﬁltered,
titred by qPCR, and stored at 280°C until use.
In vivo administration of AAV. Mice were anesthetized with an in-
traperitoneal injection of ketamine (100 mg/kg) and xylazine (10 mg/kg). A
microclamp was placed on the bile duct caudal to the liver to prevent vector
distribution. A 30-gauge needle was used to advance retrogradially through the
sphincter of Oddi into the common bile duct. A volume of 100 mL of AAV
vectors diluted in PBS was injected into the duct. A dose of 1012 vector
genomes per mouse was used.
Statistical analysis. All values are expressed as the means 6 SEM. Differ-
ences between groups were compared by Student t test. A P value ,0.05 was
considered statistically signiﬁcant.
RESULTS
Increased islet vascularization and inﬂammation
parallels enhanced VEGF production in type 2
prediabetic mice. Islet vascularization and VEGF ex-
pression were determined in 6-month-old C57Bl6 mice fed
with an HFD for 4 months. HFD-fed mice developed in-
sulin resistance, as they were normoglycemic (chow,
136 6 13.5 vs. HFD, 143 6 17.5 mg/dL) and highly hyper-
insulinemic (chow, 2.36 0.4 vs. HFD, 8.16 1.7 ng/mL) and
showed altered insulin tolerance (Supplementary Fig. 1).
In contrast to mice fed a chow diet, islets from HFD-fed
mice were larger (chow, 2906 65 vs. HFD, 4356 110 mm2;
P , 0.05), indicating compensatory islet hyperplasia. Islets
from these mice showed hypervascularization with thicker
basal membranes after staining for the endothelial cell
marker CD31 and the basement membrane marker colla-
gen IV (Fig. 1A and B). To investigate whether intraislet
vasculature was functional, a FITC-conjugated dextran
solution was intravenously injected in these mice. An in-
creased vessel area/islet area ratio (;25%) was observed
in HFD-fed mice, indicating higher islet vascularization
(Fig. 1C and D). This suggests that in hyperplasic islets,
angiogenesis might have increased to perfuse new b-cells.
This was parallel to the increased VEGF content (about
twofold) in HFD islets (Fig. 1E and F). Because VEGF can
induce collagen IV synthesis by endothelial cells (28),
VEGF upregulation was probably responsible for the in-
creased amount of endothelial ECM of these islets (Fig.
1A). Because ﬁbrosis and VEGF upregulation are also
usually found during inﬂammatory processes (11), pan-
creatic sections were stained for the macrophage cell
marker Mac-2, and an increase in macrophage inﬁltration
in the islets of HFD-induced insulin resistant mice was
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observed (Fig. 1G and H). These results suggest that in-
sulin resistance induces compensatory islet hyperplasia
together with increased islet VEGF expression, angiogen-
esis, and macrophage recruitment.
VEGF overexpression in islets leads to hyper-
vascularization, altered morphology, and inﬂam-
mation. To elucidate the role of VEGF in islet angiogenesis
and b-cell function, transgenic mice overexpressing VEGF
in b-cells under the control of the RIP-I were generated.
Two transgenic lines, VEGFlow and VEGFhigh, with a 2.7-
and 17-fold increase in VEGF expression (Fig. 2A and B),
respectively, were obtained. VEGFlow mice showed an
increase in VEGF comparable to that observed in insulin-
resistant mice (Fig. 1F) and rats (19). VEGF serum con-
centrations remained unchanged (wild-type, 221 6 27.8;
VEGFlow, 202 6 29.3; and VEGFhigh, 189 6 25.1 ng/dL),
suggesting an autocrine/paracrine effect of VEGF in the
pancreas. Compared with wild-type, 2-month-old VEGFlow
and VEGFhigh islets displayed hypervascularization and
basal membrane thickening, as shown by both CD31 and
collagen IV immunostaining (Fig. 2C). Intravascular in-
jection of FITC-conjugated dextran conﬁrmed the in-
creased vessel area/islet area ratio of functional capillaries
(Fig. 2C and D).
Islets from 2-month-old VEGFlow and VEGFhigh mice
showed altered distribution of a and b-cells (Fig. 3A). Al-
though the basal membrane of islet endothelial cells provides
signals that promote b-cell proliferation (15) and transgenic
islets were hypervascularized, the b-cell mass was similar in
wild-type, VEGFlow, and VEGFhigh mice (Fig. 3B). This was
consistent with normal rates of b-cell replication and apo-
ptosis (Fig. 3C–F). This altered islet morphology was parallel
to decreased levels of E-cadherin (Fig. 3F and G), a key
protein in maintaining islet endocrine cell contacts (29,30).
Long-term b-cell overexpression of VEGF leads to
glucose intolerance and hyperglycemia. Two-month-
old wild-type, VEGFlow, and VEGFhigh mice presented
similar glycemia, insulinemia (Fig. 4A and B), and glucose
tolerance (Fig. 4C). In addition, comparable in vivo insulin
secretion proﬁles were noted in all groups (Fig. 4D). This
was consistent with normal GLUT-2 expression in VEGFlow
islets (Fig. 4E and F). However, VEGFhigh islets showed
a decrease in GLUT-2 expression without a major change in
insulin secretion (Fig. 4E and F). Therefore, although
transgenic islets were disorganized and hypervascularized,
glucose homeostasis in young transgenic mice was never-
theless unaltered, indicating normal islet function, in
agreement with the normal b-cell mass.
FIG. 1. Hypervascularization and macrophage inﬁltration in pancreatic islets from insulin-resistant HFD-fed mice. A: Islet vessels were revealed
by dual collagen IV (red) and insulin (green) immunostaining. Arrows point to thickened basement membrane. B: Endothelial cells were
immunostained by CD31 antibody. HFD-fed mice showed more endothelial cells per islet (arrows). C: Pancreatic sections from HFD- and chow-fed
FITC-dextran–infused mice showing vessels (green) and insulin (red). Capillaries with a large lumen are shown in the inset. D: HFD animals (black
bar) showed increased FITC-dextran area/islet area compared with chow-fed mice (white bar) (n = 3/group). *P< 0.05 HFD vs. chow diet. E: VEGF
immunostaining of pancreatic sections from HFD- and chow-fed mice. F: VEGF content in protein extracts of isolated islets from individual animals
chow-fed mice (white bar) and HFD mice (black bar) was determined by ELISA (n = 4/group). HFD mice displayed a marked increase in Mac-2–
positive macrophage inﬁltration in islets as shown after immunohistochemical analysis (G) and morphometrical analysis (H) (chow-fed mice
[white bar] and HFD mice [black bar]). Inﬁltrating macrophages at the periphery and inside the islet are shown in the inset (arrows) (n = 3/group).
Scale bars, 100 mm. *P < 0.05 HFD vs. chow. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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VEGFlow mice remained normoglycemic up to 12 months
of age, when they developed mild hyperglycemia and hypo-
insulinemia (Fig. 4A and B), altered glucose tolerance, and
decreased glucose-stimulated insulin release (Fig. 5A and B),
but normal insulin sensitivity (data not shown). In contrast,
VEGFhigh mice, which expressed higher VEGF levels, de-
veloped glucose intolerance and decreased insulin secretion
after a glucose load earlier, at 5 to 6 months of age (Fig. 5C
and D). Moreover, 8-month-old VEGFhigh mice displayed
overt hyperglycemia, hypoinsulinemia (Fig. 4A and B), and
glucose intolerance (Fig. 5E).
Morphometric analysis of pancreatic sections from
VEGFlow mice showed a trend toward decreased b-cell mass
only at the age of 12 months (Fig. 5F and G), although this
FIG. 2. Increased VEGF expression in VEGFlow and VEGFhigh transgenic b-cells leads to islet hypervascularization. A: Representative Western blot
showing higher expression of VEGF in both VEGFhigh and VEGFlow. B: A 2.7- and 17-fold increase in VEGF protein levels were found in islets from
2-month-old VEGFlow and VEGFhigh mice measured by ELISA, wild-type (WT) mice (white bar), transgenic VEGFlow mice (gray bar), and transgenic
VEGFhigh mice (black bar). *P < 0.05 transgenic vs. WT (n = 8–15/group). C: Top panel: detection of endothelial cells by CD31 immunostaining.
Middle panel: collagen IV (red) and insulin (green) immunohistochemical analysis of VEGFlow and VEGFhigh islets. Bottom panel: FITC-dextran
(green) together with insulin (red) immunostaining was used to label functional islet vessels. D: Morphometric analysis revealed an increase in the
vessel area in both VEGFlow and VEGFhigh mice (n = 3/group): WT mice (white bar), transgenic VEGFlow mice (gray bar), and transgenic VEGFhigh
mice (black bar). Scale bars, 100 mm. *P < 0.05 transgenic vs. WT. (A high-quality digital representation of this ﬁgure is available in the online
issue.)
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FIG. 3. Two-month-old VEGFlow and VEGFhigh mice showed disorganization of islet architecture, but normal b-cell mass. A: Top panel: immuno-
histochemical analysis of insulin (green) and glucagon (red). In transgenic mice, islets appeared disorganized with a-cells in the core. Bottom
panel: insulin immunostaining used to visualize islet architecture. B: b-Cell mass was measured in 2-month-old mice (n = 4–7/group): wild-type
(WT) mice (white bar), transgenic VEGFlow mice (gray bar), and transgenic VEGFhigh mice (black bar). C: Ki67 (green) and insulin (red)
immunostaining were used to label proliferating b-cells (arrow). D: Percentage of Ki67-positive (replicative) b-cells. E: TUNEL (green) and in-
sulin (red) immunostaining showed apoptotic nuclei (arrow). F: Quantiﬁcation of TUNEL-positive (apoptotic) b-cells. G and H: Western blot
analysis of E-cadherin using islet homogenates from 2-month-old mice. G: A representative immunoblot is shown. H: Densitometric analysis
of three different immunoblots: WT mice (white bar), transgenic VEGFlow mice (gray bar), and transgenic VEGFhigh mice (black bar). Scale bars,
100 mm. *P < 0.05 transgenic vs. WT. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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did not reach statistical signiﬁcance (P = 0.059). In con-
trast, 8-month-old VEGFhigh mice displayed a marked loss of
b-cell mass (;80%) (Fig. 5F and G). In VEGFhigh pancreata,
insulin- and glucagon-positive cells were scattered and sur-
rounded by abundant collagen IV-positive staining (Fig. 5F).
VEGF overexpression leads to islet inﬂammation and
increased cytokine production. In addition to promoting
angiogenesis, VEGF is involved in macrophage re-
cruitment (13). Mac-2–positive cells were detected in islets
from 2- to 12-month-old VEGF mice (Fig. 6A and B).
Macrophage inﬁltration progressively increased as animals
aged and in parallel with VEGF expression, being higher in
VEGFhigh than in VEGFlow islets (Fig. 6A and B). These
results suggest that chronic overexpression of VEGF pro-
gressively increased macrophage recruitment. Consistent
with this, a statistically signiﬁcant increase in the expres-
sion of CCL-2 (monocyte chemoattractant protein-1),
IL-1b, and TNF-a was observed in islets of 12-month-old
VEGFlow mice and 5-month-old VEGFhigh mice, although
a tendency toward increased expression was already
noted in 2-month-old mice (Fig. 6C–E). Thus, the de-
velopment of hyperglycemia and decrease in b-cell mass
were concomitant with progressive macrophage in-
ﬁltration, cytokine production, and ﬁbrosis.
In vivo AAV-mediated VEGF overexpression in b-cells
of adult mice results in islet hypervascularization and
inﬂammation. To avoid potentially undesirable effects of
VEGF overexpression during embryonic development and
to verify a direct effect of VEGF in endocrine pancreas
inﬂammation, AAV vectors were used to overexpress
VEGF in islets of adult mice. Intraductal delivery of AAV
vectors of serotype 9 (AAV9) leads to highly efﬁcient and
long-term transduction of b-cells and exocrine pancreas
(31). To restrict transgene expression to b-cells, the RIP-I
promoter was used. Thus, AAV9 vectors carrying a RIP-I/
VEGF transgene were intraductally injected into 2-month-
old mice, and glucose homeostasis and islet morphology
were studied within 2 months after AAV injection. Com-
pared with AAV9-null–treated mice, AAV9-VEGF–treated
animals showed about a twofold increase (AAV9-VEGF:
2.2 6 0.8-fold increase vs. AAV9-null) in islet content of
VEGF, similar to the increases detected in islets from HFD-
fed mice, VEGFlow transgenic mice, or Zucker rats (19).
This value was, however, variable among mice paralleling
FIG. 4. Glucose homeostasis in VEGFlow and VEGFhigh mice. Blood glucose (A) and insulin (B) levels were monitored in fed mice from 2–12 months:
wild-type (WT) mice (white bar), transgenic VEGFlow mice (gray bar), and transgenic VEGFhigh mice (black bar) (n = 15 animals/group).
**P < 0.01 *P < 0.05 transgenic vs. WT. Glucose tolerance (C) and in vivo insulin secretion (D) were determined after an intraperitoneal glucose
injection (2 g/kg body weight) into 2-month-old mice WT (white circle), VEGFlow mice (gray square), and VEGFhigh mice (black square) (n = 10
animals/group). E: Immunohistochemical analysis of GLUT-2 (green) and insulin (red) in islets from 2-month-old mice is shown. F: GLUT-2 mRNA
expression from isolated islets from 2-month-old VEGFlow and VEGFhigh mice was determined by qPCR (n = 3 pools of islets from three mice per
pool): WT mice (white bar), transgenic VEGFlow mice (gray bar), and transgenic VEGFhigh mice (black bar). Scale bars, 100 mm. *P < 0.05 vs. WT
mice. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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differential efﬁciency of transduction. Despite the hetero-
geneity, all AAV9-VEGF–treated mice showed between 30
and 80% hypervascularized and disorganized islets, with
increased collagen IV accumulation (Fig. 7A). These
alterations were already observed 10 days after vector
administration (Fig. 7A) and were also present at 40 days
(Supplementary Fig. 2). Islet inﬂammation, determined by
Mac-2 immunostaining, was increased in AAV9-VEGF–
treated mice at 10 (Fig. 7A and B) and 40 days (Supple-
mentary Fig. 2) after AAV injection. Moreover, increased
VEGF expression in b-cells induced a progressive increase
in glycemia (Fig. 7C), along with glucose intolerance (Fig.
7D). Thus, these results conﬁrm that VEGF overexpression
in islets of adult mice can induce hypervascularization,
islet disorganization, and inﬂammation that result in im-
paired glucose homeostasis.
DISCUSSION
In the preliminary stages of T2D, expansion of b-cell mass is
a key adaptive response to compensate for insulin re-
sistance (2). During this period, islet vasculature also needs
to expand to perfuse the newly formed b-cells. The de-
velopment of vessels in adult organisms (angiogenesis)
occurs through a multistep process requiring VEGF and
other soluble factors (32). In this study, we found that islets
from obese, insulin-resistant, HFD-fed mice displayed in-
creased vascularization that paralleled increased VEGF
levels. Similar observations were described in insulin-
resistant prediabetic Zucker rats (32), in which islets of these
rats showed increased vascularization and enhanced VEGF
secretion compared with non–insulin-resistant rats. This
may indicate that VEGF upregulation represents a compen-
satory response to support angiogenesis during b-cell
FIG. 5. Glucose homeostasis in VEGFlow and VEGFhigh mice was impaired with age. Glucose tolerance (A) and insulin in vivo secretion (B) were
measured in 12-month-old wild-type (WT) (white circle) and VEGFlow mice (gray square) (n = 12 animals/group). *P < 0.05 VEGFlow vs. WT mice.
Glucose tolerance (C) was determined in parallel to in vivo insulin secretion (D) after a glucose load (2 g/kg body weight [b.w.]) in 5-month-old WT
mice (white circle) and transgenic VEGFhigh mice (black square). At this age, VEGFhigh mice were normoglycemic, but showed impaired insulin
release and glucose intolerance after the glucose load (n = 12 animals/group). *P < 0.05 VEGFhigh vs. WT mice. E: Eight-month-old VEGFhigh mice
(black square) were glucose-intolerant compared with age-matched WT (white square) mice as shown by a glucose tolerance test (1 g/kg b.w.) (n =
10 animals/group). *P < 0.05 VEGFhigh vs. WT mice. F: Top panel: representative images of insulin immunostaining of islets. Middle panel: im-
munohistochemical analysis of insulin (green) and glucagon (red) expression. Bottom panel: immunohistochemical analysis of collagen IV (red)
and insulin (green). Islets from 12-month-old WT and VEGFlow and 8-month-old VEGFhigh mice are shown. Scale bars, 100 mm. G: b-Cell mass was
determined by insulin immunostaining in 8- and 12-month-old VEGFlow and 8-month-old VEGFhigh mice and compared with age-matched WT mice, as
indicated in RESEARCH DESIGN AND METHODS (WT mice [white bar], transgenic VEGFlow mice [gray bar], and transgenic VEGFhigh mice [black bar]) (n = 3
sections/mouse and 4 animals/group). **P < 0.001 VEGFhigh vs. WT mice, #P < 0.1 VEGFlow vs. WT. (A high-quality digital representation of this
ﬁgure is available in the online issue.)
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expansion. To discern the role of increased VEGF and islet
vascularization during T2D development, VEGFlow and
VEGFhigh transgenic mice were generated. Similar to
HFD-fed mice, VEGFlow and VEGFhigh mice displayed
islet hypervascularization with irregular capillaries and thicker
basal membranes. These vascular alterations resembled
those observed in islets from HFD-fed mice and were con-
sistent with pathologic angiogenesis. Similarly, it has been
α
FIG. 6. VEGF-overexpressing islets showed progressive inﬂammation. A: Macrophage inﬁltration was determined by Mac-2 immunostaining in
islets from 2-month-old wild-type (WT), VEGFlow, and VEGFhigh mice (top panel) and 12-month-old WT and VEGFlow and 8-month-old VEGFhigh mice
(bottom panel). B: Quantiﬁcation of Mac-2–positive area in pancreas sections from 2-, 8-, and 12-month-old WT, in 2-, 8-, and 12-month-old
VEGFlow, and in 2- and 8-month-old VEGFhigh mice (n = 4 animals/group): WT mice (white bar), transgenic VEGFlow mice (gray bar), and transgenic
VEGFhigh mice (black bar). C–E: Islets from VEGFlow and VEGFhigh mice displayed increased expression of key inﬂammatory cytokines. CCL-2 (C),
IL-1b (D), and TNF-a (E) were measured by qPCR from isolated islets from 2- and 12-month-old VEGFlow and 2- and 5-month-old VEGFhigh mice
(n = 4 pools of islets from three mice per pool): WT mice (white bar), transgenic VEGFlow mice (gray bar), and transgenic VEGFhigh mice (black
bar). Scale bars, 100 mm. *P < 0.05 vs. age-matched WT mice. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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shown in tumors that prolonged deregulated expression of
VEGF leads to aberrant immature vessels that often invade
the surrounding tissue (33,34). In contrast, normal vascula-
ture spreads by physiologic angiogenesis, requiring proper
regulation of the dose and timing of VEGF production (11,32).
Islets from transgenic VEGFlow and VEGFhigh mice
showed thickening of the vessel basal membrane that
resulted from increased collagen IV accumulation, which
in VEGFhigh islets disrupted islet structure and was parallel
to b-cell loss and development of hyperglycemia. In islets
from GK rats, ECM deposition develops from intra- and
peri-islet vessels (21,35). The islet ECM is mainly synthe-
sized by endothelial cells, because b-cells do not have an
ECM (25,26). Moreover, VEGF is able to induce collagen IV
synthesis in cultured endothelial cells (28), which suggests
that in islets from VEGF transgenic mice, a VEGF-mediated
activation of endothelial cells causes overproduction of
ECM components and ﬁbrosis. Similarly, islet ﬁbrosis has
FIG. 7. AAV-mediated VEGF overexpression in b-cells increased islet vascularization and inﬂammation. Two-month-old wild-type (WT) mice were
injected with VEGF-expressing (AAV9-VEGF) or nonexpressing (null) AAV9 vectors (1012 vector genomes/mouse). A: Ten days after AAV injection
vasculature structure was revealed by immunostaining for collagen IV (red) and insulin (green) (top panel). VEGF-treated islets showed increased
basement membrane compared with AAV-null. FITC-dextran (green) together with insulin (red) immunostaining was used to label functional
blood vessels (top middle panel). Insulin (green) and glucagon (red) expression showed islet disorganization (bottom middle panel). Macrophage
inﬁltration in AAV-VEGF–treated animals was determined by Mac-2 immunostaining 10 days after AAV injection (bottom panel). Scale bars,
100 mm. B: AAV-VEGF–injected animals showed increased Mac-2–positive area/islet area when compared with AAV-null–treated mice as early as 10
days after injection: AAV-null–treated mice (white bar) and AAV-VEGF–treated mice (black bar) (n = 4 mice/group). C: Fed blood glucose levels
were determined before AAV injection (day 0) and at several time points thereafter: AAV-null-treated mice (white circle) and AAV-VEGF–treated
mice (black square) (n = 10 mice/group). D: Glucose tolerance was measured 20 days after AAV administration (2 g/kg body weight) (n = 10
animals/group). *P < 0.05 VEGF vs. null. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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also been described in islets of patients with T2D and in
various spontaneous rodent models of T2D, such as db/db
mice and Zucker and GK rats, in which it is involved in islet
destruction (21,36–38). Thus, during T2D, chronic VEGF
upregulation in islets may be responsible for ECM accu-
mulation in surrounding islet vessels, leading to ﬁbrosis.
Two-month-old VEGFlow and VEGFhigh mice also dis-
played disorganized islets with a-cells scattered in the
islet core. The Ca2+-dependent cell adhesion molecule
E-cadherin, which is highly expressed in pancreatic islets,
mediates b-cell-to-b-cell contacts, controlling islet archi-
tecture and function (29,30). The expression of E-cadherin
was reduced in VEGFlow and VEGFhigh islets, consistent
with decreased numbers of direct b-cell-to-b-cell contacts
and islet disorganization. It is widely accepted that proper
insulin secretion requires the coordinated function of the
b-cells that form an islet (29). Moreover, islet disorgani-
zation is considered a hallmark of islet dysfunction (39).
However, despite altered islet architecture, 2-month-old
VEGFlow and VEGFhigh mice displayed normal in vivo
insulin release and glucose tolerance. Therefore, these
transgenic mice indicate that abnormal islet morphology is
not directly responsible for impaired b-cell function. Be-
cause the alteration of insulin secretion developed in par-
allel with the severity of inﬂammation, our results suggest
that islet inﬂammation, rather than islet disorganization
alone, was probably the proximate cause of islet failure.
Although the precise mechanism or more likely multiple
mechanisms underlying decreased b-cell mass and func-
tion in T2D remain to be elucidated, islets from patients
with T2D display an inﬂammatory process characterized
by the presence of immune cell inﬁltration, inﬂammatory
cytokines, apoptotic cells, and, eventually, ﬁbrosis. VEGF
transgenic mice partially recapitulate those processes that
occur speciﬁcally in the islets without the development of
insulin resistance. VEGF is a powerful chemoattractant for
macrophages and other leukocytes at the sites of angio-
genesis, where these cells play an important role in vessel
formation and tissue remodeling (13,40). Islets from HFD-
fed mice showed inﬁltrating macrophages, comparable to
those described in islets from several type 2 diabetic ani-
mal models and human patients (7,38,41,42). Increased
numbers of macrophages are detectable very early in islets,
before the onset of diabetes (41). Normoglycemic insulin-
resistant HFD-fed mice showed islet macrophage inﬁltration
concomitant with VEGF upregulation. Similarly, islets from
both VEGFlow and VEGFhigh mice were progressively inﬁl-
trated by macrophages. Moreover, Mac-2+ insulitis grade and
VEGF upregulation level in VEGFlow mice were similar to
those observed in prediabetic HFD-fed mice. Finally, VEGF
transgenic islets showed macrophage inﬁltration even be-
fore developing impaired glucose homeostasis, suggesting
that inﬁltration is not a consequence of b-cell death.
Therefore, this study suggests that macrophage inﬁltration
may already be induced during islet hyperplasia and play
a role in initiating and/or accelerating b-cell failure. This
hypothesis is supported by the AAV-mediated over-
expression of VEGF in islets of adult mice, because, as early
as 10 days after vector administration, mice already showed
islet disorganization and inﬂammation, which subsequently
progressed to hyperglycemia and glucose intolerance.
VEGF-expressing islets showed macrophage inﬁltration
and increased expression of IL-1b, CCL-2, and TNF-a. A
signiﬁcant increased in cytokine expression was detected
at a slightly delayed time compared with macrophage in-
ﬁltration, but both inﬂammatory processes increased with
age and VEGF levels. Macrophages are able to secrete a
broad range of cytokines. In RIP-CCL2 transgenic mice, my-
eloid cell inﬁltration of islets is able to induce b-cell death and
diabetes (43). Moreover, it has been shown that high glucose
concentrations can induce b-cell expression of several cyto-
kines, such as IL-1b and CCL-2 (44–46). Thus, during de-
velopment of T2D, VEGF and inﬂammatory cytokines may be
secreted and attract macrophages, and, in turn, macrophages
can produce higher levels of proinﬂammatory cytokines.
These processes probably stimulate each other in a positive-
feedback manner, and, together with other processes such as
endoplasmic reticulum (ER) stress, may contribute to b-cell
failure and death. During T2D, higher insulin requirements
and high circulating levels of free fatty acids and glucose can
lead to the activation of the unfolding protein response and
ER stress within the b-cells (47). Moreover, several studies
have proposed that proinﬂammatory cytokines are also able
to induce b-cell apoptosis by means of ER stress (47–49).
Because VEGF overexpression in islets from our transgenic
mice resulted in enhanced cytokine production, this may also
contribute to b-cell loss through ER stress.
It is of interest that although previous reports demon-
strated that decreased VEGF expression in b-cells resulted
in insufﬁcient vascularization leading to impaired insulin
secretion and glucose intolerance (14), our results suggest
that excessive islet VEGF production also triggers archi-
tectural abnormalities and impaired b-cell function. Thus,
VEGF levels need to be ﬁnely and tightly regulated to
avoid development of undesirable hypervascularization,
ﬁbrosis, and inﬂammation.
Finally, although no direct links between angiogenic
factor genetic variants and diabetes have been reported,
allelic variants of VEGF (50) and the VEGF-inducer tran-
scription factor hypoxia inducible factor-1a have been
described in T2D patients (51). Moreover, polymorphisms
in the VEGF-A gene have been reported in patients with
micro and macrovascular diabetic secondary complica-
tions (52,53). These data further suggest that dysregulation
of VEGF could be involved in the pathogenesis of T2D.
In summary, the current study demonstrates a crucial
role for islet vascularization and inﬂammation in the de-
velopment of b-cell failure, suggesting that macrophage
recruitment and sustained islet cytokine production may
result from increased angiogenesis and/or VEGF upregu-
lation and that this inﬂammatory process may contribute
to connect insulin resistance with b-cell death and T2D.
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